
Pharma Launch Pricing Strategist
Build defensible pricing strategies and payer value arguments for pharma launches
What You Can Do
You develop comprehensive pricing frameworks that connect your product's clinical benefits to monetary value, anticipated payer objections, and regulatory requirements. Claude synthesizes clinical efficacy data, real-world economic evidence, and competitive positioning into structured arguments ready for cross-functional stakeholder alignment and payer engagement.
Features
Create tiered pricing strategies (base, premium, risk-sharing) with clinical and economic justification
Structure NICE, ICER, G-BA, and CADTH-ready health economic value arguments from trial data
Build response matrices addressing reimbursement concerns before payer negotiations
Position pricing against standard-of-care alternatives with market intelligence
Generate pricing scenarios with breakeven analysis and payer acceptance probabilities
Cross-functional alignment framework covering finance, medical, and commercial teams
Geographic and payer-type segmentation strategy with timing recommendations
Example Output
Pricing Strategy Framework Output:
- Executive summary with recommended launch price range ($X–$Y) justified by clinical superiority and QALY thresholds
- Value dossier template: Clinical Efficacy → Health Economic Model → Payer Affordability Assessment
- Objection-response matrix: "Price too high vs. SOC" → Response: "ICER analysis shows $X/QALY at premium pricing"
Payer Communication Example: "Our Phase III data shows 35% response rate improvement vs. standard-of-care (p<0.01). Economic modeling indicates cost-per-QALY of £28,000 at proposed $X price—well within NICE thresholds. Risk-sharing framework available for uptake flexibility."
Scenario Analysis Output: Base Case: $X/unit, 60% payer acceptance; Premium Case: $Y/unit, 40% acceptance; Risk-Share Case: $Z/unit (outcomes-linked), 75% acceptance.
What's Included
- SKILL.md instruction file with clinical-to-pricing workflow:
- Pricing Strategy Template (framework, assumptions, sensitivity triggers):
- Value Dossier Outline (HTA-body aligned format with health economic structure):
- Payer Objection-Response Matrix (pre-populated with pharma market access challenges):
- Launch Readiness Checklist (clinical evidence validation, pricing alignment gates, stakeholder sign-off):
- Competitive Pricing Benchmark Tool (SOC comparators, pricing positioning worksheet):
Who It's For
- Pricing & Market Access Analysts — Structuring launch strategies and payer communications
- Market Access Managers — Building health economic arguments for reimbursement bodies
- Commercial Strategy Teams — Competitive positioning and launch scenario planning
- Health Economics & Outcomes Research (HEOR) Professionals — Translating trial data into economic models
- Regulatory & Reimbursement Affairs Leads — Preparing evidence dossiers for HTA submissions
Best For
- Pre-launch pricing strategy development (Phase III near-completion through launch)
- Health economic value dossier creation for NICE, ICER, G-BA, CADTH submissions
- Payer negotiation preparation and objection-response planning
- Competitive pricing benchmarking vs. standard-of-care alternatives
- Cross-functional alignment materials (finance, medical, commercial) and launch readiness validation







